Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of
GVAX Immunotherapy for Pancreatic Cancer
SOUTH SAN FRANCISCO, Calif., June 04, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announcedfollow-up data from a Phase 2 clinical trial of
GVAX immunotherapyfor pancreatic cancer which was conducted by the Johns HopkinsSidney Kimmel Cancer Center. The trial enrolled 60 patients withoperable pancreatic cancer who received
GVAX after surgicalresection of their tumor and adjuvant...
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces
a Broad, Patient-Specific Antibody Response
SOUTH SAN FRANCISCO, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immuneresponse data from two previously conducted Phase 2 clinical trialsof
GVAX immunotherapy for prostate cancer. Evaluation of antibodyresponses in patients with advanced prostate cancer from thesestudies shows that the
GVAX cell-based immunotherapy inducesantibody responses to a bro...
Cell Genesys Provides Final Median Survival Data From Second Phase
2 Trial of GVAX Immunotherapy for Prostate Cancer
SOUTH SAN FRANCISCO, Calif., April 03, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final,updated results from its second multi-center Phase 2 trial of
GVAXimmunotherapy for prostate cancer which evaluated escalating dosesof the immunotherapy in 80 patients with metastatichormone-refractory prostate cancer (HRPC). Additional follow-up ofthe 22 patients who received th...